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5. Relapse when the drug is discontinued is common. A
careful follow-up and immediate resumption of therapy and its
prolonged use may be necessary.
6. It is concluded that Tofranil is a relatively safe (non-toxic)
drug which is of particular value in the treatment of the pre-
dominantly endogenous type of depressive state.
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TABLE r. RESULTS OF TREATMENT
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relaxation (chlorpromazine, reserpine, meprobamate); or they
have an excitatory effect promoting increased activity (ampheta-
mines).
Tofranil
Recently, several reports have been published on the use of
a new antidepressive drug, imipramine (G22355 or Tofranil).t
Tofranil (N-(3-dimethylaminopropyl) irninodibenzyl hydrochloride)
belongs to the new group of iminodibenzyl derivatives. The
clinical effect of Tofranil resembles an 'unblocking' and brighten-
ing of the fixed depressive mood..Although no specific pharmaco-
logical basis for its action has yet been established, it is thought
that Tofranil acts on the pathological mechanism characteristic
of depression and interrupts its further progress.
t These reports are briefly discussed in an a.rtide by Dr. M. Russell Clarke.
which is published on page 990 of this issue of the Joumal.
Previous Daily Side-effects
Case Sex Age Diagnosis treatmen{ dosage Results
M 45 Manic-depressive ECT See below Recovery il
(depressed)
2 M 40 Manic-depressive ECT See below Poor Nil
(depressed)
il3 M 45 Manic-depressive ECT See below Recovery
(depressed)
4 M 54 Manic-depressive ECT See below o change il
(depressed)
5 M 50 Manic-depressive ECT See below Treatment Agitation
(depressed) stopped
6 M 48 Manic-depressive ECT See below Improvement Nil
(depressed)
7 M 44 Reactive depression ECT *See below Recovery Nil
8 M 46 Reactive depression ECT See below Marked il
improvement
9 M 58 Senile psychosis ECT See below Marked Nil
(depressed) improvement
10 M 66 Senile psychosis ECT See below Marked Nil
(depressed) improvement
11 M 67 Senile psychosis ECT See below Treatment il
(depressed) stopped
12 M 47 Involutional ECT See below o change il
melancholia
13 M 53 Involutional ECT See below o change il
melancholia
14 M 59 Involutional ECT See below No change Nil
melancholia
15 M 46 Involutional ECT See below Treatment Nil
melancholia stopped
16 F 61 Reactive depression il See below Marked il
improvement




18 F 48 Reactive depression ECT See below Recovered Restlessness
19 F 47 - Reactive depression 'il See below Recovered il
20 F 56 Reactive depression ECT See below Recovered Restlessness
21 F 53 Reactive depression il See below Recovered il
THE USE OF TOFRANIL IN MENTAL HOSPITAL PRACTICE
Dosage = 100 mg. daily, increasing to a maximum of 250 mg. daily. thereafter decreasing until maintenance dose of 100 .. 150 mg. attained, given orally.
• = The mg. dosage given in this case was the same as in all other cases with the exception that a combination of tablets and ampoules were used.
Over the ktst few years there has been an appreciable increase in
the admission rate to hospitals of patients suffering from depres-
sive conditions. Until now only electric convulsive therapy (EC1),
together with psychotherapy, have provided any degree of success
in-the treatment of these depressive states. As a result of the
overcrowding of mental hospitals, the shortage of medical staff,
and the limited facilities for treating these conditions in general
hospitals and private practice, these methods of treatment have
not been exploited fully. Moreover, ECT is sometimes contra-
indicated by some coneomitant organic disease.
Up to this stage the results obtained with psychopharmaco-
logical drugs in the treatment of the depressive conditions have
been most disappointing; their action being slight or indeed
completely absent. However. these drugs often have a beneficial
effect on anxiety and restlessness, producing tranquillity and
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CLINICAL EXPERIENCE
My. obst:rvations on G22355 (Tofranil) were carried out on 21
patIents m Valkenberg Hospital. Fourteen patients were chronic
cases over the age of 40, and 7 patients were recent admissions.
The dosage. schedule was as follows: 100 mg. daily, increased to
250 mg. daily, thereafter decreasing to maintenance dose of 100-
150 mg. daily. The time tafen for improvement varied be-
tween 4 days and 3 weeks.
Side-t:ffects wer.e minimal. One patient complained of dizziness.
A maI1:'c-depr~lve (depressed) patient became highly agitated
and actIvely sUIcidal, probably due to the fact that Tofranil cleared
the psychomotor inhibition.
In ? patients (recent admissions with reactive depression),
the on~a1 symptoms became accentuated and they complained
of ~ fee~ng of fear. However, on continuation of therapy these
patien~s Imp~oved markedly and were discharged. In 3 cases therapy
w~ dlsco~tmued because of coincidental physical illness, the
patients bemg removed to a clinic. No allergic reactions developed.
'f!le drug did not interfere with sleep. Photosensitivity and visual
dIsturbances due to its atropine-like action have been reported,
but the general toxicity is claimed to be low.
A summary of the results of the cases treated in a trial series
are given in Table 1.
RESULTS
Of the 21 cases treated (Table 1), 8 recovered, 5 showed a marked
improvement, in 3 treatment was stopped because of physical
:easons, and in 5 there was no change. Excluding the 3 patients
ill whoIJOl treatment was stopped, this represents a recovery and
marked Improvement rate of 72%. The following are examples of
!he results. of treatment in a case of recent onset of symptoms, and
III a chromc case:
CaseI
. This male patient, a recent admission, aged 44 years, presented
~lf at the Cape Me~tal Health Clinic, Cape Town, com-
pl~g of gross depressIOn coupled with numerous hypochon-
driacal symptoms. It was obvious that he was basically a neurotic
person and that he was suffering from a reactive depression.
He was admitted to Valkenberg Hospital as a voluntary patient
and after only 4 days began to show a marked improvement.
The gross depression lifted and his other complaints became
minimal. .After a further week's treatment he requested to go
apd wa;; d~scharged. He has been seen at an out-patients' clinic
smce hIS discharge, and he has maintained his improvement.
Case 2
A man, aged 54, who has been an inmate ofValkenberg Hospital
for the past 10 years. He was originally admitted in a state of
gross. depression associated with hallucinations and persecutory
delUSIOns. Despite numerous courses of ECT, little or no im-
provement was noted.
Before treatment \vith Tofranil he was dull, dejected, inhibited
in all his actions, full of petty complaints and had always to be
coaxed to eat. After some 3 weeks of treatment he became brighter
and generally more active. He began to help. in routine ward
work and ate without prompting. He has maintained his im-
provement on a maintenance dose.
DISCUSSION
The results obtained in treating this smau series of cases have
proved most gratifying. The best results were obtained in recent
admissions although satisfying results were also obtained in
long-standing chronic cases.
Recently we have combined Tofranil with ECT for the treatment
of severely depressed cases with the most encouraging results.
Moreover, we encountered no unpleasant side-effects: Kielholtz
and Battegayl state that when the action of Tofranil is insufficient,
its combination with ECT is recommended since Tofranil reduces
the number of treatments required. I is interesting to note that
in the trial series many cases responded remarkably well to Tofra:lil
alone after ECT had failed. Azima' states that about 80% of
patients formerly requiring .ECT may no longer require this
treatment as the result of the introduction of Tofranil.
From the above observation it would appear that- Tofranil
has a place in the treatment of hospitalized cases of depression,
and that it is useful in out-patient and office practice, especially
in treating cases of reactive depression where facilities for psycho-
therapy and ECT are limited.
SUMMARY
1. Tofranil has a definite place in the treatment of depressive
states.
2. It will undoubtedly prove useful in out-patient clinics,
especially in the treatment of cases of reactive depression.
3. It has been successfully used in combination with ECT for
the treatment of severely depressed cases.
4. In combination with promazine derivatives it will be of
use to counteract depressions caused by these derivatives in certain
cases.
5. The side-effects are minimal. Special attention should,
however, be given to the danger of suicide, which is potentially
present in every case of depression, since Tofranil mav remove
psychomotor retardation. -
6. In the present series the recovery/improvement rate was
72%.
The material for lhis trial was liberally supplied by l1le Pharmaceutical Division
of the J. R. Geigy S.A., Basel. Switzerland.
I wish to l1lank Dr. T. E. Cheze-Brown, Physician Superintendent, Valken-
berg Hospital, Observatory, Cape, for having made it possible for me to carry
out l1lis trial, and l1le Commissioner for Mental Hygiene for permission to pub-
lish.
REFERENCES
I. Kielholtz, P. and Ballegay, R. (1958: Schweiz. med. Wschr., 88, 763.
2. Azima, H. {I959) : Canad. Med. Assac). J., 80, 535_
ASSOCIATION OF NEUROLOGISTS, PSYCIDATRISTS AND NEUROSURGEONS (M.A.S.A.):
PRESIDENT'S REPORT·
B. CROWHURST ARCHER, M.D., President
I should like, first, to offer our congratulations to Dr. B. P. Pienaar
on his appointment as Commissioner for Mental Hygiene for the
Union of South Africa and to thank him personally for all the
support he. has given us throughout the year, both as Com-
missioner, and as a member of the South African Medical and
Dental Council.
I should also like to congratulate Prof. A. M. Lamont on his
appointment as Deputy Commissioner for Mental Hygiene and
as Professor of Psychiatry at the University of Pretoria.
To Prof. L. A. Hurst, our congratulations and best \vishes on
his appointment as the first full-time Professor of Psychiatry at
the University of Witwatersrand. We are confident that this
appointment \vill do much to facilitate the integration of psychiatry
into the teaching of general medicine, and pave the way to similar
appointments in our medical schools throughout the Union.
It has been my pleasant task to announce officially that our
Vice-president, Dr. Morris Ginsburg, Physician-Superintendent,
Sterkfontein Hospital, Krugersdorp was eh:cted-the first TravelJing
Fellow in Psychiatric Medicine of the College of Physicians,
Surgeons and Gynaecologists of South Africa and, on your behalf,
I wish him every success on his important mission to Europe and
America.
. I should also like to thank Dr. A. P. Blignault for his great help
to us in the literary field and to congratulate him on his appointment
as Editor of the South African Medical Journal.
Mental Health Service
The theme adopted by the World Health Organization for the
year 1959 was 'Mental Illness and Mental Health in the World
Today'. It is therefore fitting.that I should review briefly what our
Group has done in the past year to lay the foundations of a mental
health service, which is so urgently required to meet the ever
increasing problem of mental illness in this country.
The first essential in any mental health service is, not only to
provide good guidance, diagnosis and treatment, but also to offer
good teaching and training facilities for medical practitioners,
nurses and auxiliary workers. For this reason we welcome the
